. The presentation and progress of ALS varies between individuals but, typically, patients present with disability in one part of the body, followed by progression that leads to involvement of other regions 2, 3 
. Typically, these clinical milestones tend to occur at predictable time points over the disease course, with a median of 3-7 months spent at each milestone 3 . Although average survival in ALS is only 2-4 years, some patients have a more slowly progressive disease form and can survive for over a decade 1, 2, 4 , emphasizing the importance of symptomatic management throughout the course of the disease.
An extensive search for a treatment to modify the relentlessly progressive course of ALS has been unrewarding, with riluzole being the only drug shown to offer a small survival benefit of approximately 3 months 5, 6 . In the absence of an effective treatment, the overall aims of care are to maximize physical functioning and improve quality of life. The focus of care can change as the disease progresses; understanding the disease progression enables the clinician to predict when care priorities are likely to change and to pre-empt complications. In the 75% of individuals who present with limb-onset weakness, the initial focus of care can include providing physical therapy, assistive aids and relief of physical symptoms, such as cramps and spasticity. Later in the disease, more complex interventions are required, such as noninvasive ventilation (NIV) and (usually at even later stages) gastrostomy feeding. In 25% of individuals, bulbar dysfunction, which causes speech and swallowing disturbance, is the presenting feature. These patients require early speech therapy and optimization of communication and nutrition. Gastrostomy tends to be required earlier in the disease course than in patients with limb-onset disease.
In the past two decades, clinical guidelines for ALS management have been developed [7] [8] [9] [10] [11] [12] . However, in the absence of strong evidence for the majority of treatments, recommendations have largely been based on
Noninvasive ventilation (NIV)
The provision of bilevel inspiratory and experiatory ventilatory support through the patient's upper airway using a mask.
Supportive and symptomatic management of amyotrophic lateral sclerosis
Esther V. Hobson 1 and Christopher J. McDermott 1 Abstract | The main aims in the care of individuals with amyotrophic lateral sclerosis (ALS) are to minimize morbidity and maximize quality of life. Although no cure exists for ALS, supportive and symptomatic care provided by a specialist multidisciplinary team can improve survival. The basis for supportive management is shifting from expert consensus guidelines towards an evidence-based approach, which encourages the use of effective treatments and could reduce the risk of harm caused by ineffective or unsafe interventions. For example, respiratory support using noninvasive ventilation has been demonstrated to improve survival and quality of life, whereas evidence supporting other respiratory interventions is insufficient. Increasing evidence implicates a causal role for metabolic dysfunction in ALS, suggesting that optimizing nutrition could improve quality of life and survival. The high incidence of cognitive dysfunction and its impact on prognosis is increasingly recognized, although evidence for effective treatments is lacking. A variety of strategies are used to manage the other physical and psychological symptoms, the majority of which have yet to be thoroughly evaluated. The need for specialist palliative care throughout the disease is increasingly recognized. This Review describes the current approaches to symptomatic and supportive care in ALS and outlines the current guidance and evidence for these strategies.
. The reasons for improved outcomes with integrated care are unclear, but the survival benefits could relate, in part, to the complex decision-making processes and communication that can take place within a colocalized team 15 .
Attendance at a multidisciplinary clinic may also reduce and shorten hospital stays, is associated with an increased likelihood of the use of riluzole, assistive aids and NIV, and, in one study, improved quality of life 13, 15, 16 . Furthermore, patients value the convenience and quality of unified care. However, although offering appointments with multiple specialists during a single visit reduced travel time, travelling to hospital and the prolonged nature of appointments remains a problem 17, 18 . Alternative services, such as telemedicine or remote monitoring, could be useful to sustain access to specialists throughout the disease, without the need to travel 19 .
Symptomatic treatment
In the early stages of ALS, management focuses on maximizing function, promoting independence and treating symptoms. For most symptoms, little ALS-specific evidence exists, so standard treatments are recommended, with choice influenced by the individual's other ALS symptoms and comorbidities 10 . For example, amitriptyline can be particularly useful in patients experiencing pain and excessive saliva. Even though medical treatment for some symptoms may be ineffective, early recognition remains important because it enables provision of support, education and coping strategies for patients and carers, as well as shared decision-making and advance planning.
Physical symptoms
Cramps. A Cochrane review found no evidence to recommend any particular treatment in ALS-associated cramps, which are a common symptom of the disease 20 . Quinine is the most commonly used therapy but its use for cramps is restricted in the USA because of reports of rare but serious haematological and cardiac events (665 serious events and 93 deaths between 1969 and 2006) 21 . A further Cochrane review of quinine in patients with various causes of cramp reported some evidence that quinine was safe and effective 22 . The adverse effects of quinine are dose-dependent, and the low doses of quinine used in the management of cramps may not necessarily be associated with the serious adverse effects reported in the USA. Alternatively, the studies included in the review could be too small to detect very rare events. In the absence of an effective alternative, the American Academy of Neurology recommends that quinine can be used in ALS, but only as a last resort 7 . UK guidelines recommend using quinine as first choice, whereas European guidelines recommend a trial of levetiracetam first, based on the findings of one small study 10, 12, 23 . More recently, a small trial, published in 2016, suggested that low-dose mexiletine was well tolerated and reduced the frequency of cramps 24 .
Spasticity. Management of spasticity aims to reduce the impact of increased muscle tone and prevent complications, such as pressure sores or contractures 25, 26 . Attention should be paid to treating aggravating factors (such as constipation or pain), as well as to posture and seating. Physiotherapy, including passive stretching, can be helpful. One randomized controlled trial of 25 patients indicated that prescribed exercise was associated with small improvements in disability and spasticity 27 . 
Key points
• The aim of the management of ALS is to maximize quality of life and minimize morbidity • Guidelines for symptomatic care are becoming more evidenced-based • Management by a specialist, clinic-based multidisciplinary team is associated with improved survival • In patients with respiratory failure, noninvasive ventilation prolongs survival and improves quality of life • Nutritional status is an independent predictor of survival and, if patients opt for enteral feeding, early gastrostomy insertion is recommended before significant weight loss takes place • Cognitive impairment is common in ALS and is associated with a worse prognosis; the optimal management of this problem is unclear
Pharmacological treatments are often prescribed, but evidence for their efficacy is lacking. Muscle relaxants (such as baclofen and dantrolene) should be used cautiously because they can exacerbate muscle weakness and their sedating side effect is often significant 10, 12 . To promote tolerance and compliance, we support a 'startlow, go slow' approach 26 . Observational studies suggest that if oral medication has failed, intrathecal baclofen can improve symptoms and quality of life [28] [29] [30] . Pain. Pain is commonly reported in all stages of ALS (57% of patients in one study 31 ) and becomes more common as the disease progresses 31 . Pain is most commonly experienced in the limbs, trunk and neck, and is associated with joint immobility, pressure sores and cramps 31, 32 . Pain interferes with all aspects of daily functioning and often goes under-recognized and undertreated. An improved understanding of the mechanisms of pain in ALS is required, as well as evidence to determine the 
Behavioural variant of FTD
The predominant symptoms of this disorder are executive dysfunction and behavioural changes.
effectiveness of different analgesics 31, 32 . In the absence of ALS-specific evidence, we recommend a structured approach, using the WHO Analgesic Ladder 32, 33 . All major categories of analgesia can be used; treatments can be selected according to the causes and severity of pain, increasing the potency of drugs as required. Opioids seem safe and effective and do not necessarily shorten life; moreover, they can also be useful in relieving dyspnoea 34, 35 .
Cognitive and other neurological deficits
Overlap between ALS and other neurodegenerative diseases, in particular frontotemporal dementia (FTD) and parkinsonism, is increasingly recognized. The presence of multiple neurodegenerative diseases in a patient with ALS or in their family should alert the clinician to the potential presence of abnormally long hexonucleotide repeat expansion C9ORF72 (REFS [36] [37] [38] . This recently identified genetic abnormality occurs in approximately 7% of patients with sporadic ALS and in 39% of those with a family history of ALS 39 . Approximately 10-15% of patients with ALS show signs of FTD (although not all of them have the C9ORF72 expansion); typically behavioural variant of FTD 40 . A further 50% experience mild cognitive or behavioural changes. Patients with executive dysfunction have a worse prognosis, and behavioural changes have a negative impact on carer quality of life 40, 41 . Screening for cognitive deficits is recommended, because it enables the provision of patient and carer sup port 8, 10, 12 . Standard memory tests, such as the Mini-Mental State Examination, are insensitive to fronto temporal deficits 42 . A number of validated ALSspecific cognitive screening tools exist, such as the ALS-Cognitive Behavioural Screen (ALS-CBS) and the more extensive University of California San Francisco (UCSF) Screening Battery 42 . The Edinburgh Cognitive Assessment Screen (ECAS) tool also includes the carer 43 . However, examining cognition, behaviour, language and affect is time-consuming and most tools covering all aspects of ALS require at least 30 minutes to complete 42 . According to one cohort study, other types of neurological dysfunction, including ataxia and autonomic dysfunction, were observed in 14% of patients with ALS. Individuals with these additional problems also had a poor prognosis 44 . Currently, no evidence exists to guide management of cognitive or other neurological deficits in ALS, and establishing evidence-based strategies to manage such symptoms should be a priority for further research. 
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Environmental controls
Electronic assistive technology that enables people with significant disabilities to independently access equipment in their environment, such as home or hospital.
Eye-gaze grids
A basic form of communication aid where a patient points to or looks at letters on an alphabet board in order to spell out words.
Eye-gaze software
Computer software that tracks eye movements allowing the patient to navigate and control a computer by tracking where they are looking.
Voice banking
A software records multiple examples of the patients voice to synthesize a voice similar to the patients' own, which can be used as a replacement when using communication software.
Psychological symptoms
Approximately half of patients with ALS experience emotional lability, pathological laughter or crying; such symptoms are more common in those with bulbaronset ALS 45 . Two randomized controlled trials of 20 mg dextromethorphan in combination with 10 mg quinidine, including a total of 333 patients with ALS, found a notable reduction in emotional events 46, 47 . Adverse effects included dizziness and somnolence, which led to 24% of patients to discontinue the treatment in one study 46 . Dextromethorphan-quinidine treatment is recommended for use in the USA, but should be avoided in those at risk of cardiac arrhythmia, as it can prolong the QT interval 8 . In territories in which dextromethorphanquinidine combination is unavailable, selective serotonin reuptake inhibitors (such as citalopram) and amitriptyline are recommended, as they have been successfully used for many years 10, 48, 49 . Other psychological symptoms are common and have a negative impact on quality of life. These include depression (reported in 11-75% of patients), anxiety (up to 33% of patients) and fatigue (75-83% of patients) [50] [51] [52] . A small trial suggested that modafinil can be safely used for fatigue 53 . Otherwise, in the absence of ALS-specific evidence, multidisciplinary management including psychological support, palliative care and physical therapy is recommended 12 , along with standard drug treatments used in other diseases.
Adaptive and assistive devices Defining the requirements for devices An array of rehabilitative strategies, assistive devices and environmental controls are available to meet the changing needs of patients with ALS. However, systematic evaluation of such interventions is lacking -even more so than in any other area of ALS care. Access to technologies is also limited by lack of awareness and the confidence and technological literacy of patients and clinicians 54 . Uptake and use of particular devices or orthoses is often poor because they have been designed for individuals with other conditions, without consideration for the needs of individuals with ALS. Teams involving designers, patients with ALS and clinicians can collaborate to develop devices that have been specifically designed to meet user needs. This user-centred approach was used recently in development of a supportive neck collar, the Sheffield Support Snood, for individuals affected by neck weakness (FIG. 2) 55,56
.
Communication aids
Augmentative assistive communication devices increase patients' quality of life and can improve carer experience and reduce burden 57, 58 . Access to specialist communication aids remains variable. Selection and support of the correct equipment that meet the needs of the patient requires specialist expertise. Some patients prefer simple systems such as writing boards, microphones or eye-gaze grids. More complex solutions, such as text-to-speech apps, voice recognition and eye-gaze software can be used by most patients who have a standard computer or tablet device.
Voice banking can provide a more natural voice to patients who use text-to-speech apps. Patients can use software (for example, Model Talker www.modeltalker. org/) to record their own voice. However the quality of the synthesized voice relies on patients recording 1,600 phrases, which is time-consuming. Alternatively, individuals can adopt a 'donated' voice; moreover, voice banks are now able to combine multiple voices to provide a voice matched to age, sex and accent; however, there is some way to go before communication devices are fast enough to maintain a conversation and produce a voice that can match the prosody of natural speech 59 . In the future, brain-computer interfaces could allow patients with severe disability to communicate via controlling of their EEG activity to produce signals. At present, this technology has been evaluated in only a small number of patients, mostly in experimental environments 60 . The potential of brain-computer interfaces is limited by the usability and reliability of the technology, and use of the devices requires extensive training and patient effort, which is particularly problematic for patients who are frail, or who have rapidly progressing disease or executive dysfunction.
Optimizing nutrition and swallowing Malnutrition and weight loss are poor prognostic factors in ALS [61] [62] [63] [64] . Reasons for weight loss include muscle wasting, poor food intake owing to dysphagia, upper limb weakness and poor appetite 65 . Poor oral intake is compounded by an increased resting energy expenditure observed in ALS 61, 66, 67 . Results of a small pilot study in gastrostomy-fed patients with advanced disease suggest that a high-calorie intake could offer a survival advantage 68 . If dietary manipulation does improve survival, Nature Reviews | Neurology it is likely to be most effective if introduced early in the disease. However, it is unknown whether these diets would be tolerated by patients without a gastrostomy.
It is recommended that patients undergo regular assessment of swallowing and weight and receive advice on diet and swallowing techniques 10 . Exercises to improve cough and swallowing, and even insertion of autologous myoblasts into the tongue with the aim of improving tongue strength are being explored [69] [70] [71] . In a study of 20 patients, botulinum toxin injections into the upper oesophageal sphincter reduced signs of aspiration 72 , but the results have not yet been confirmed in larger trials.
Gastrostomy feeding
Enteral feeding is commonly used to sustain nutrition and medication intake, but it is not been convincingly shown to improve survival, nutritional outcomes or quality of life 73 . In one study, nearly all patients and carers felt that gastrostomy insertion was beneficial to them because it relieved the anxiety associated with poor oral intake; moreover, in a few cases where oral intake had become impossible, they felt that it had kept the patient alive and in good health 74 . Given that enteral feeding is already extensively used in ALS, a randomized controlled trial with a placebo arm to definitively establish the benefits of gastrostomy feeding seems unlikely to occur.
Timing of gastrostomy insertion. For patients who opt for insertion of a gastrostomy tube -the most appropriate form of long-term enteral feeding -the optimal timing and method of gastrostomy have become clearer following a prospective cohort study of 345 patients who underwent gastrostomy insertion 75 . It concluded that, in patients whose disease is progressing, delaying gastrostomy exposes an individual to increased procedural risk with little nutritional benefit 10, 75 . Previous guidelines recommended that a loss of 10% of body weight should trigger insertion of a gastrostomy tube 7 , however, in this cohort, the majority of patients who had lost more than 10% of their premorbid body weight did not regain weight and often continued to lose weight following gastrostomy 75 . Therefore, if gastrostomy is considered, the gastrostomy tube should be placed at an earlier stage, at a recommended threshold of 5% weight loss: after this point, further weight loss can be associated with irreversible metabolic changes, making regaining weight less likely 75 .
Technique for gastrostomy tube insertion. The technique for gastrostomy tube insertion depends on a patient's respiratory function and available expertise. Endoscopic placement of a percutaneous gastrostomy (PEG) is appropriate for patients without respiratory failure who can tolerate sedation. Many patients, particularly those with limb-onset disease have respiratory impairment by the time they develop bulbar dysfunction, meaning that PEG insertion can be unsafe. Radiologically guided gastrostomy (RIG) avoids the need for sedation, but the balloon-retained tubes carry the risk of becoming displaced, leakage, or requiring replacement. Per-oral image-guided gastrostomy can be performed with sedation while the patient is on NIV. This procedure involves inserting a nasogastric tube as a guide to enable a robust PEG gastrostomy tube to be pulled through and out of the abdominal wall 73 . All three methods seem equally safe 75 .
Promoting patient choice. Identifying the correct time for gastrostomy insertion is challenging. Patients, particularly those who still enjoy the taste and the social importance of eating, often choose to delay insertion 76, 77 . Gastrostomy use also represents an important milestone in patients' disease and places a major burden on carers 74, 75 . Promoting choice is important, and conservative management should be an option for all patients. Some patients do decline gastrostomy, and gastrostomy insertion in patients who are frail or nearing the end of life is likely to be futile in addition to the fact that insertion carries a higher risk of complications. Gastrostomy insertion should not generally be undertaken in patients with severe cognitive impairment, because dysphagia or disinclination to eat is a manifestation of the end-stages of dementia 78 . However, fears that a patient with failing bulbar function will starve or choke to death means there may be pressure on clinicians to offer gastrostomy insertion even when it is likely to be futile. The alternatives to gastrostomy and concerns regarding starvation or choking should be addressed in advance, and support be offered to both the patients and those caring for them. Alternatives to gastrostomy, such as nasogastric feeding or subcutaneous fluids, can be considered and may allay some of these fears; however, such alternatives should be used with caution, given that they may, in fact, have a negative impact on the patient's quality of life. The focus should be on palliative measures aimed at relieving distress, which can help patients who are unlikely to benefit from gastrostomy 10 . These include supporting oral intake where possible and treating symptoms such as mouth dryness with good oral hygiene, NIV humidification, artificial saliva products and adjusting treatments for excessive oropharyngeal secretions.
Detection and management of respiratory failure Type 2 respiratory failure is the most common cause of death in ALS. NIV (FIG. 3) was the first intervention for ALS shown to have a positive impact on both survival and quality of life 79 . Symptoms of respiratory failure can develop insidiously, and initially, respiratory failure often only occurs in rapid eye movement (REM) sleep, causing sleep disordered breathing
. Later in the disease, patients develop dyspnoea at rest, poor cough and respiratory tract infections. These problems are exacerbated by bulbar dysfunction. Early trials of drugs that could improve respiratory muscle contractile force and cough effectiveness are underway 80, 81 .
Monitoring of respiratory failure
Given that initiation of NIV early in the course of respiratory failure confers a survival advantage 82, 83 , close monitoring of respiratory function is recommended. Respiratory function should be monitored regularly (at least every 3 months) by enquiring about symptoms of respiratory failure and using objective measures of respiratory function 7, 10, 12 . In some clinics, access to objective measures is limited and some measurements can be insensitive to respiratory failure or unsuitable for patients with bulbar or cognitive dysfunction 84 . The most basic objective measures for routine screening are forced vital capacity or sniff-nasal-inspiratory pressure
. If a patient exhibits signs or symptoms of respiratory failure, guidelines recommended that they undergo arterial or capillary blood gas analysis 12 . It should be noted that oxygen desaturation usually occurs late in type II respiratory failure and daytime measurements of arterial carbon dioxide do not necessarily reflect overnight function 79 . Therefore, if respiratory failure is suspected and daytime gas analysis is normal, nocturnal oximetry studies should be conducted 12, 85 . Noninvasive transcutaneous measurement of carbon dioxide levels is now possible and can supplement the information from overnight oximetry 86 .
Noninvasive ventilation
A randomized controlled trial of patients with ALS using NIV demonstrated survival and quality of life benefits 79 (FIG. 4) . Using NIV initially at night and also, if required, in the daytime, was associated with a median survival gain of 7 months; moreover, NIV initiation improved quality of life -an improvement that was sustained throughout the disease course.
Using NIV can be challenging: it requires perseverance by patients and carers as well as significant support from specialists 87, 88 . Unsurprisingly, patients with poor adherence or poor ventilation fail to gain a survival benefit 89 . Patients in the first trial assessing NIV in ALS with poor bulbar function failed to experience a survival benefit, but did experience improvement in quality of life 79 .
Results from a cohort study of 929 patients with ALS, published in 2015, suggested that NIV was, in fact, associated with longer survival in individuals with bulbar-onset disease 90 . It is, therefore, recommended that a trial of NIV should be offered to patients even if it is felt that NIV is likely to be difficult to tolerate 12 . When initiating NIV, it is important to address problems such as dry mouth, oropharyngeal secretions or claustrophobia, all of which affect NIV use. Additional equipment such as humidifiers or alternative masks should be available, and battery packs and back-up ventilators can reduce the burden on everyday life and allow patients to travel 12 . Face-to-face training can be supplemented by online resources such as myNIV (www.mymnd.org.uk), which promotes the benefits of NIV use and encourages adherence (FIG. 3) .
Respiratory and oropharyngeal secretions
Excessive oropharyngeal and respiratory secretions occur in approximately half of patients attending ALS clinics 91 . Anticholinergics are commonly prescribed Nature Reviews | Neurology 
Breath stacking
A technique to improve lung recruitment and cough: multiple inspiratory breaths are taken in succession and held (rather than exhaled) until full lung capacity is reached and exhalation is then allowed; the effectiveness of the process can be improved by using lung-recruitment bags.
to reduce excess secretions, but a balance needs to be reached as treatment can over-dry the mouth and thicken secretions, making respiratory secretion clearance more difficult 91 . Intraglandular botulinum toxin has been shown to be effective in reducing secretions in a randomized controlled trial of 20 patients; moreover, botulinum toxin could reduce aspiration [92] [93] [94] . The effectiveness of the treatment can be improved by using ultrasound guidance 94 . Botulinum toxin treatment can, in rare cases, worsen dysphagia and tends to be reserved for patients with a gastrostomy 91, 93, 95 . Radiotherapy is effective but its use is limited by availability and risk of permanent dry mouth 96, 97 . Guidelines recommend the use of mucolytics (such as carbocysteine) and airway humidification (via NIV or using nebulised saline) for treatment of respiratory secretions 7, 10, 12 , but evidence for their use is lacking.
Cough augmentation
Bulbar and respiratory muscle weakness leads to weakened cough and poor secretion clearance, increasing the risk of respiratory infections. Monitoring cough effectiveness with measures such as peak cough flow can identify patients at risk of ineffective sputum clearance 98, 99 . Improving lung recruitment and thereby increasing peak cough flow and sputum clearance can be achieved by using NIV and breathing exercises, such breath-stacking, which can be assisted by using a lung volume recruitment bag (FIG. 5) . Mechanical insufflation-exsufflation devices (such as Cough Assist) are more effective in increasing peak cough flow, but are difficult to use in patients with poor bulbar function 100, 101 . External high frequency chest wall oscillation, using a wearable vest, may also improve sputum clearance 102 . Guidelines suggest that cough augmentation is recommended in those with poor cough during acute infective episodes 7, 10, 12 ; however, the benefits of any of these interventions in either acute episodes or for regular prophylactic use are yet to be robustly established.
Diaphragmatic pacing
Diaphragmatic pacing involves stimulating the weakened diaphragm with external electrodes that are placed on the undersurface of diaphragm in a laparoscopic surgery. It was proposed that pulsed stimulation of the diaphragm might condition the weakened diaphragm muscle and restore coordination of respiration, which in ALS is lost as a result of upper motor neuron dysfunction 103 . In 2011, the FDA gave approval for use of a diaphragmatic pacing device in patients with ALS under the Humanitarian Device Exemption program 104 . The approval was based on partially published data from a nonrandomized uncontrolled cohort of 86 patients with ALS, which reported a positive effect of diaphragmatic pacing on survival and sleep quality 104 . However, in 2014, a randomized controlled trial of diaphragmatic pacing in the UK found that patients using pacing survived on average 11 months compared with 22.5 months in those who did not undergo pacing 103 . Subsequently, a trial in France was terminated early following similar findings of pacing-associated excess mortality 105 . A US study has suspended recruitment while the implications of the conflicting results are explored, and a post marketing approval registry study continues 106, 107 . Although pooled data from these trials could determine whether pacing could be beneficial for a subgroup of patients, for the majority of patients, diaphragmatic pacing appears to be harmful.
Care at the end of life
The experience at the end of life can have a significant impact on patients and their families [108] [109] [110] . Clinical trials in palliative care have many ethical and practical challenges, and guidance is based on expert consensus 8, [10] [11] [12] . Owing to the complexities of the management of advanced ALS, guidelines recommend that specialist palliative care services are involved early and throughout the disease 8, 10, 12, 35 . Patients welcome the ability to participate in advanced planning, which enables them to discuss and document their attitudes towards future events and medical interventions; however, enactment of these wishes is not always straightforward, and decisions should be reviewed regularly 35, 111 . Patients' preferred place of death is usually at home, but distressing symptoms, unanticipated crisis or increasing carer burden can make end-of-life care at home challenging 35 . Advanced planning, good communication and access to expertise in palliative and social care, particularly out of office hours, can avert crises and promote a peaceful death. Anticipatory prescribing of symptomatic therapies in a range of routes (including via gastrostomy, transdermal patches or subcutaneous infusions) is encouraged 112 (TABLE 2) . The Motor Neuron Disease Association (UK) has developed a "Just-in-case" box in which medication can be stored in a patient's home 113 . Carers or clinicians (such as ambulance practitioners or nurses) can then use these medications to treat terminal symptoms.
Invasive ventilation
With progression of respiratory muscle weakness, some patients use NIV almost continuously to ease breathlessness. Others find that NIV and cough augmentation techniques fail to control their symptoms. Patients can undergo tracheotomy tube insertion and invasive ventilation in a desire to improve these symptoms and prolong life. Triggers for this procedure include being unable to tolerate NIV, difficult-to-manage respiratory secretions or an emergency such as a respiratory crisis 114 . One cohort study suggested that invasive ventilation can offer survival advantage for young patients, but offers no survival advantage for individuals over 60 years 115 . Uptake of tracheotomy ventilation varies across the world and is influenced by cultural beliefs and health care infrastructure. Concerns that the patient and carer quality of life can be poor and that patients could become 'locked-in' , losing the ability to communicate, also contribute to the fact that tracheotomy use in ALS is relatively uncommon [114] [115] [116] . Following prolonged use of invasive ventilation, communication does become difficult and can become impossible 117 . Therefore, effective communication aids (such as eye-gaze software or in the future, possibly brain-computer interfaces) must be provided and patient's preferences for end of life decisions must be established.
Noninvasive ventilation the end of life
The use of NIV at the end of life warrants special consideration. Some patients die peacefully with ventilation in situ, whereas others simply stop using NIV without experiencing significant difficulties 110 . However, in a proportion of patients, the decision to discontinue ventilation is more complex. Having made a decision to stop using NIV, patients may require the assistance of others, for example to remove the mask. Individuals who have used NIV continuously are likely to require treatment to prevent distressing symptoms after stopping NIV, and such treatment needs to planned and administered in advance. Similar to the difficulties discussed regarding gastrostomy choices, withdrawal of therapy can cause concerns on legal and ethical grounds, which can interfere with the delivery of the best end-of-life care 11, 118 . The law in many countries recognizes that a patient with capacity can opt to refuse or withdraw from medical treatment, or receive treatment for distressing symptoms, even if it potentially hastens death. Continuation with treatment against the patient's wishes would be illegal.
Guidelines are available to advise those clinicians considering NIV withdrawal 11, 118 . It is recommended that patients, family and clinicians openly discuss their thoughts about ventilation and the circumstances at the end-of-life. These discussions should begin before ventilation commences and continue throughout the illness. Discussions can be further triggered by situations such as initiation of ventilation in the daytime or using NIV to relieve dyspnoea, or if topics such as 
Euthanasia
With the patient's consent, a doctor acts directly to end the patient's life, for examply by administering a lethal injection.
Refusal or withdrawal of treatment
At the patient's request, treatment can be declined or withdrawn, even if the lack of treatment has the potential to hasten the patient's death.
Physician-assisted suicide
A doctor knowingly and intentionally provides a person with the knowledge, means, or both required to commit suicide, for example by counselling about lethal doses of drugs, prescribing such lethal doses or supplying the drugs.
advanced decision-making or euthanasia are raised. If a patient expresses a wish to withdraw from ventilation, the patient's capacity must be assessed and it must be established that the decision is the settled position of the individual. Ideally this should involve several discussions with different senior health professionals 11 . Care must be taken to ensure the patients have sufficient time and support to understand the available treatment options and consequences of their decision and communicate their wishes. To avoid distressing symptoms, opioids and/or benzodiazepines should be used to achieve conscious sedation (drowsy but awake) before ventilation withdrawal. Deep unconscious sedation may be necessary to tolerate withdrawal in those patients who become breathless quickly after mask removal. Although patients can die quickly, preparations must be made to support patients in case the process takes longer 118 .
Physician assisted suicide and euthanasia
Unlike refusal or withdrawal of treatment, physician-assisted suicide and euthanasia are legal in only a limited number of countries 35 . Although many patients seek these options, the desire to shorten their life is usually diminished if their underlying concerns and fears regarding their disease are identified and addressed, directly highlighting the need for end-of-life discussions throughout the disease course. Patients can be reassured that symptoms can be managed effectively, and most patients die peacefully 35 .
Carer support
Informal carers (usually spouses) provide the majority of care for those with ALS. This role has a significant negative impact on carers' physical and emotional wellbeing, burden and quality of life [119] [120] . Carer distress increases with patient distress and with disease progression, and when they are faced with behavioural problems or they lack social and medical support. Carers identify the need for provision of information and training in subjects such as manual handling, as well as the availability of respite care, counselling and access to trained paid-for care 121 .
No interventions have been demonstrated to positively impact on carers' lives, and the potential increased burden posed by interventions that require a high level of carer support such as NIV or gastrostomy feeding should be considered. Carers should receive information about ALS, be involved with decision-making and have their own psychological, social and financial needs assessed and addressed 12 .
Future priorities
Understanding the specific detail of how best to deliver the interventions described in this Review, such as multidisciplinary care, NIV and nutritional support, is essential to ensure patients derive the benefits 122 . Given the clear evidence of benefit of noninvasive ventilation, improving the assessment and optimization of respiratory function should be a priority. A further priority should be an effort to evaluate rehabilitative strategies, such as speech therapy programmes and device provision. These are a core part of the care of every individual with ALS and yet there is little or no evidence to guide best practice.
Although improvements have been made over the past decade, access to effective treatments remains variable. Before 2006, few patients in the UK were using NIV, but following a definitive trial and subsequent publication of evidence-based guidelines, NIV use has increased 9, 79, 84, 123 . Similar improvements have been demonstrated in Italy but, as with riluzole prescribing, improvements were mostly made in tertiary centres and NIV remains less often used by patients not attending specialist clinics 15, 124 . Focus must therefore be on both improving evidence-based guidelines and promoting their use in order reduce inequalities in healthcare provision for individuals with ALS.
Promoting evidence-based practice should also reduce the potential for patients to be harmed by using unsafe, untested treatments. For example, before the recent studies demonstrating the potential of harm caused by diaphragmatic pacing, systems for this treatment were already being widely installed around the world. This story has several lessons: the most important is that all interventions should be evaluated appropriately and this will usually be in the context of a randomized controlled study. The arguments that patients with ALS have nothing to lose and that they have a right to try untested therapies are understandable, given the poor prognosis of ALS and the lack of curative treatments 125, 126 . Many US states have passed legislation permitting patients with terminal illnesses to try unapproved experimental treatments or devices under certain conditions 126 . There are concerns that such approaches can lead to patient harm and become a barrier to the development and evaluation of effective therapies 126, 127 . As the evidence base for supportive care increases, individual decisions become more complex. Patient choices are further complicated by the wealth of information on unproven or untested therapies available on the Internet. Patients often use these sources to make decisions about their medical care 128, 129 . In order to 
Conclusions
Supportive care for patients with ALS is best delivered by a specialist multidisciplinary team, which can provide holistic care to patients, family and carers, maximizing function and quality of life. However, further work is needed to strengthen the evidence base for the management of many aspects of ALS, which ultimately should ensure universal good practice and reduce inequalities in care. 
